-
Conditions
Interventions
topical Tranexamic acid : inject Tranexamic acid 1,
000 mg ( 20 ml. ) at posterior surface of decorticated laminae after close the sheath. ,0.9%NaCl 20 ml. injected at posterior surface of decorticated laminae after close the sheath.
Experimental Drug,Placebo Comparator Drug
topical tranexemic acid,normal saline
Sponsors
none
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: a.Men and women, 18 to 70 years of age with injuries involving the thoracic or lumbar spine (Thoracolumbar Injury Classification and Severity score  5) undergoing long-segment (4 levels) instrumented posterior spinal fusion with local autologous bone graft b.No neurological deficits c.American Society of Anesthesiologists physical status class I, II or III
Exclusion criteria
Exclusion criteria: a.Renal insufficiency b.History of thromboembolic events (e.g., pulmonary embolism, embolic stroke, and deep venous thrombosis) c.History of significant cardiovascular diseases (e.g., unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension) d.History of acquired defective color vision e.Coagulation disorder f.Gross hematuria or microhematuria g.Dural tear h.Allergy to tranexamic acid i.Take aspirin or nonsteroidal anti-inflammatory drugs within a week before randomization and during the study period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative PRC transfusion day 1,2,3 postoperatively unit | — |
Secondary
| Measure | Time frame |
|---|---|
| postoperative blood loss day 1,2,3 postoperatively ml. | — |
Contacts
Public Contactterdpong tanaviriyachai
none
Outcome results
None listed